Professor Merab Kokaia’s proof-of-concept study has been published in Molecular Therapy: Methods & Clinical Development
The results of the study show that CG01 has clinically relevant anti-seizure effects On February 19th 2018 Professor Merab Kokaia, one of CombiGene’s scientific founders, together with lead scientist Esbjörn Melin presented final data from the preclinical...read more
This is an article from Ingenious number three. Read the whole Ingenious here >> CombiGene has recently taken two major steps towards the first studies in humans, so-called clinical studies. The first step has been to identify a suitable CDMO (Contract...read more
Significant advances in the epilepsy project. Inlicensing of a new gene therapy project. Acquisition of Panion Animal Health.
This is an article from Ingenious number three. Read the whole Ingenious here >> Jan Nilsson, CombiGene’s CEO, is in a characteristically good mood when he sits down at the conference table for this interview with Ingeneious. It’s obvious that a lot is happening...read more
The Report >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish...read more
CombiGene publishes offer document with respect to the offer to the holders of shares and warrants in Panion Animal Health
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares or warrants be accepted from or on behalf of holders in Australia, Brazil, Canada, Faroe Islands, Hong Kong, India, Japan, New...read more
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.